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According to recent statistics, breast cancer remains one of the leading causes of death among
women in Western countries. Breast cancer is a complex and heterogeneous disease, presently
classified into several subtypes according to their cellular origin. Among breast cancer histotypes,
infiltrating ductal carcinoma represents the most common and potentially aggressive form. De-
spite the current progress achieved in early cancer detection and treatment, including the new
generation of molecular therapies, there is still need for identification of multiparametric bio-
markers capable of discriminating between cancer subtypes and predicting cancer progression
for personalized therapies. One established step in this direction is the proteomic strategy,
expected to provide enough information on breast cancer profiling. To this aim, in the present
study we analyzed 13 breast cancer tissues and their matched non-tumoral tissues by 2-DE. Col-
lectively, we identified 51 protein spots, corresponding to 34 differentially expressed proteins,
which may represent promising candidate biomarkers for molecular-based diagnosis of breast
cancer and for pattern discovery. The relevance of these proteins as factors contributing to breast
carcinogenesis is discussed.
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1 Introduction
The application of proteomic strategies to cancer detection
and other clinical purposes is now holding a focal position.
The main reason is the complexity of cancer biology, which
results in the consistently observed heterogeneous responses
to therapies across patient populations. Within female
populations of Western countries, breast cancer is the most
frequent type of cancer. Breast cancer is not a single disease,
but includes several different forms that can be grouped into
invasive and non-invasive histotypes. Among the invasive
ones, ductal infiltrating carcinoma is the most common and
aggressive form [1]. The evolution to a malignant phenotype
involves mutation and/or misexpression of a variety of genes
controlling cell proliferation, differentiation and death.
However, since the transcriptional activity of a gene does not
necessarily reflect cellular protein expression, the identifica-
tion and quantification of proteins are essential steps for the
understanding of molecular events leading to malignant
transformation. In fact, different protein factors can be over-/
underexpressed simultaneously and can activate/deactivate
distinct cell functions. Consequently, biomarker searching
and tumor profiling of breast cancer are the ultimate goals in
the scientific community, necessary for defining phenotypic
characteristics of individual cancers and for a better predic-
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tion of the clinical outcome. The standard clinical and path-
ological approaches to breast cancer staging are the AJCC
(American Joint Committee on Cancer) criteria of tumor
size, axillary lymph node status, and presence or absence of
distant metastases. Other validated predictive factors include
the assessment of the estrogen receptor, progesterone recep-
tor, and epidermal growth factor receptor 2 (ErbB2). Unfor-
tunately, no single marker has sufficient predictive value for
breast cancer evolution. Indeed, patients with the same type
and stage of disease often display significantly different clin-
ical typologies and responses to therapy. This emphasizes
the need to identify multiparametric biological markers for
more accurate cancer detection and management. The pro-
teomic approach, based on 2-DE combined with protein se-
quencing, is one of the most promising techniques for the
identification of protein species related to malignancy, and
has provided powerful analytical tools for identifying the dif-
ferentially expressed and/or post-translationally modified
proteins as potential biomarkers in tumors (reviewed in [2]).
With this aim, in the present study we analyzed 13 breast
cancer tissues and their matched non-tumoral tissues by
2-DE. Collectively, we identified 51 protein spots, corre-
sponding to 34 differentially expressed proteins. These were
grouped into eight categories based on the closest affinity for
their major biological functions, namely: (i) cytoskeleton and
associated proteins; (ii) metabolic enzymes; (iii) molecular
chaperones; (iv) proliferation and differentiation regulators;
(v) detoxification and redox proteins; (vi) protein degrada-
tion; (vii) other proteins; and (viii) serum proteins. The
seventh group contains proteins which have no clear classi-
fication at present.
Relative expression levels of differentially expressed pro-
teins between tumoral and non-tumoral tissues were con-
sidered statistically significant according to the Student’s
t-test.
We suggest that this new approach of generating differ-
ential proteomic profiles, based on functional categories, is
of interest for two reasons: firstly, for its obvious contribu-
tion to the biomarker detection, and secondly because it
offers new insights into the molecular biology of breast
cancer.
2 Materials and methods
2.1 Clinical specimens
Sample management was performed according to the bio-
ethical recommendations. Aliquots of breast cancer and its
adjacent non-tumoral tissues were obtained during surgical
intervention and immediately frozen in liquid nitrogen and
stored at –807C until use. The patients did not receive any
cytotoxic/endocrine treatment prior to surgery. In each case,
non-tumoral tissue was located at least 5 cm away from the
primary tumor. Diagnosis of ductal breast cancer (G2/G3)
was confirmed histopathologically.
2.2 Sample preparations
The frozen breast tissue samples were washed several
times with PBS and homogenized in RIPA buffer (50 mM
Tris pH 7.5, 0.1% Nonidet P-40, 0.1% deoxycholate,
150 mM NaCl, 4 mM EDTA) and a mixture of protease
inhibitors (0.01% aprotinin, 10 mM sodium pyropho-
sphate, 2 mM sodium orthovanadate, 1 mM PMSF). The
extraction was carried out overnight at 47C with the same
buffer. The total cellular lysate was centrifuged at
15 000 rpm for 20 min to clear debris and the supernatant
was dialyzed against ultrapure distilled water, lyophilized
and stored at –807C until analysis. Protein concentration
in the cellular extracts was determined using the Bradford
method [3].
2.3 2-DE
The proteins extracted from breast cancer tissue and normal
adjacent tissue were solubilized in a buffer containing 4%
CHAPS, 40 mM Tris, 65 mM DTE (1, 4-Dichioerythritol) in
8 M urea. Aliquots of 45 mg (analytical gels) or 1.5 mg (pre-
parative gels) of total proteins were separately mixed with
350 mL of rehydration solution containing 8 M urea, 2%
CHAPS, 10 mM DTE and 0.5% carrier ampholytes (Resolyte
3.5–10), and were applied for IEF using commercial sigmoi-
dal IPG strips, 18 cm long with a pH range 3.5–10. The sec-
ond dimension was carried out on 9–16% linear gradient
polyacrylamide gels (SDS-PAGE), and the separated proteins
were visualized by ammoniacal silver staining.
2.4 Image acquisition and data analysis
Silver-stained gels were digitized using a computing densi-
tometer and analyzed with ImageMaster 2D Platinum soft-
ware (Amersham Biosciences, Sweden). Gel calibration was
carried out using an internal standard and the support of
the ExPASy molecular biology server, as described else-
where [4]. Quantitative variations in protein expression
levels were calculated as the volume of the spots (i.e., inte-
gration of OD over the spot area). In order to correct for
differences in gel staining, spot volumes relative to the sum
of the volume of all spots on each gel (%Vol) were calculated
by the software. The differences in expression between
breast cancer and normal adjacent tissues were analyzed by
the Student’s t-test; p values ,0.05 were considered signifi-
cant (*), p,0.01 highly significant (**) and p,0.001 very
highly significant (***).
2.5 Protein identification
N-terminal microsequencing was performed by automated
Edman degradation in a protein sequencer (Procise, 419
Applied Biosystems), as described elsewhere [5].
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3 Results and discussion
Although many studies in the last few years have been per-
formed to detect phenotypic changes occurring in the multi-
stage carcinogenesis of the mammary gland, more informa-
tion is still needed concerning extensive proteomic profiling
of cancer tissues as distinguished from non-tumoral coun-
terparts to be used for patient stratification and monitoring.
In the present study we report the comparative proteomic
profiles of 13 pairs of surgical samples obtained from
patients with ductal infiltrating breast cancer, histologically
diagnosed as G2/G3 grade. Figure 1 shows the miniatures of
Figure 1. Panel showing the miniatures
of the 2-D matching maps from 13 sur-
gical specimens of BCT and its NAT. 2-D
separation was performed on IPG gel
strips (18 cm, 3.5–10 NL) followed by the
SDS-PAGE on a vertical linear-gradient
slab gel (9–16 %T).
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the proteomic maps of the 13 paired samples. Here it is pos-
sible to observe that the cancer-derived proteomics display a
far higher level of complexity than non-tumoral tissues:
around 1200 protein spots were detected by the ImageMaster
software in the non-tumoral tissues, while an average of 1500
were detectable in the cancer tissues.
Figure 2 shows one representative proteomic pair,
among the 13 matched pairs of breast cancer and non-
tumoral adjacent tissue. The protein identities are marked
with labels corresponding to the abbreviated name of the
Swiss-Prot database. Fifty-one protein spots, corresponding
to 34 distinct proteins, were identified in the maps. The pro-
tein identity was assessed by N-terminal sequencing and by
gel matching with reference maps previously obtained in our
laboratory, where identification was performed by N-termi-
nal microsequencing and by MALDI-TOF [5]. Matching vali-
dation was made by Western blotting with anti-actin and
anti-enolase (not shown), which occupy a strategic position
on proteomic maps and are among the proteins used as
internal standard for map calibration, and by N-terminal se-
quencing of six randomly selected protein spots, among the
ones previously identified, (namely, TPIS acidic form,
GSTP1, SODM, THIO, and two isoforms of UBIQ).
The identified proteins, listed in Table 1, are grouped
into eight functional categories, according to our previously
described criteria [6]: (i) cytoskeleton and associated proteins
(ii) metabolic enzymes; (iii) molecular chaperones; (iv) pro-
liferation and differentiation regulators; (v) detoxification
and redox proteins; (vi) protein degradation; (vii) other pro-
teins; and (viii) serum proteins.
To compare the pattern and intensity of protein expres-
sion between the paired samples of breast cancer and non-
tumoral tissues we applied the densitometry algorithm of the
ImageMaster software, using the %Vol parameter in order to
avoid interfering staining differences between the maps [7].
Figures 3–10 show the collection of differentially expres-
sed protein spots between breast cancer tissues (BCT) and
non-tumoral adjacent tissues (NAT). The panel displays the
cropped images from 2-D gels alongside the densitometric
graphs, analyzed using the Student’s t-test; *p,0.05 was
considered significant; **p,0.01 was considered highly sig-
nificant, and ***p,0.001 very highly significant. The data in
the graphs are expressed as mean number 6 SD.
3.1 Cytoskeleton and associated proteins (Fig. 3)
The proteins identified within this category are ACTB/G,
TPM2, TPM4 and a short form of ACTB/G and of TAGL2. As
already reported [6], beta and gamma actin are not distin-
guishable in the map, since they are highly homologous,
differing by only four amino acids at the amino-terminal
region. In both proteins, the mature forms are N-terminal
blocked and this precludes their N-terminal sequencing by
Edman degradation, which would have offered unequivocal
identity of each isoelectric form and the possibility of dis-
criminating between the two gene products. Therefore, we
Figure 2. Representative proteomic maps of the matched BCT
and NAT derived from a random select patient. Protein spots of
known identity are labeled with the abbreviated name of the
Swiss-Prot database. When present, different isoforms of the
same protein are jointly labeled. sf = short form.
applied both designations, B and G, to the actin forms
detected in the present maps. Generally, we detected three
isoelectric variants of ACTB/G in the silver-stained gels.
Interestingly, two of them appear significantly overexpressed
in all the tumor tissues, while one of three shows no signifi-
cance level, indicating a high variability among the patient’s
proteomic profiles.
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Table 1. Catalogue of the protein spots identified in the proteomic maps of the 13 pairs of breast cancer and healthy tissues, whose pro-
totypes are reported in Fig. 2. The protein names, accession numbers (AC) and abbreviated names correspond to the nomen-
clature used in the Swiss-Prot database.
Protein name AC number Abbreviated
name
Exp. pI/MW
(theoretical)
ID
methodsa)
N-terminal
residues
1. Cytoskeleton and associated proteins
Actin, cytoplasmic 1,2 P60709/P63261 ACTB/G 5.16/42 000 (5.29/41 736) 1, 3
Actin, cytoplasmic 1,2 P60709/P63261 ACTB/G 5.20/42 000 1, 3
Actin, cytoplasmic 1,2 P60709/P63261 ACTB/G 5.23/42 000 1, 3
Actin, cytoplasmic 1,2 sf P60709/P63261 ACTB/G sf 5.56/36 548 2 res. 62–71
Transgelin-2 sf P37802 TAGL2 sf 5.61/13 186 (6.63/21 117) 2 res. 12–26
Tropomyosin alpha 4 chain P67936 TPM4 4.78/33 145 (4.67/28 391) 3
Tropomyosin beta chain P07951 TPM2 4.81/41 527 (4.66/32 851) 3
2. Metabolic enzymes
Alpha enolase P06733 ENOA 6.46/46703 (6.99/47 037) 1, 3
Alpha enolase P06733 ENOA 6.66/45 935 1, 3
Alpha enolase P06733 ENOA 6.82/45 631 1, 3
Fructose-bisphosphate aldolase A P04075 ALDOA 7.29/37 688 (8.39/39 289) 3
Fructose-bisphosphate aldolase A P04075 ALDOA 7.34/37 627 3
Glyceraldehyde-3-phosphate dehydrogenase P04406 G3P2 7.39/35 500 (8.58/35 922) 2 res. 2–7
Glyceraldehyde-3-phosphate dehydrogenase P04406 G3P2 7.52/35 500 2 res. 2–11
Glyceraldehyde-3-phosphate dehydrogenase P04406 G3P2 7.59/31 720 2 res. 2–21
Phosphoglycerate kinase 1 P00558 PGK1 7.32/41 323 (8.30/44 483) 3
Phosphoglycerate kinase 1 P00558 PGK1 7.31/41 326 3
Triosephosphate isomerase P60174 TPIS 6.53/25 000 (6.51/26 538) 2 res. 1–5
Triosephosphate isomerase P60174 TPIS 6.81/25 000 2 res. 1–10
3. Molecular chaperones
Calreticulin P27797 CRTC 4.52/59 300 (4.29/48 142) 3
Peptidyl-prolyl cis-trans isomerase A P62937 PPIA a 7.04/14 500 (7.82/17 881) 3
Peptidyl-prolyl cis-trans isomerase A P62937 PPIA b 7.19/14 500 3
4. Proliferation and differentiation regulators
14-3-3 protein zeta/delta P63104 1433Z a 5.23/16 955 (4.73/27 745) 3
14-3-3 protein zeta/delta P63104 1433Z b 5.50/16 124 3
SH3 domain-binding glutamic acid-rich-like protein O75368 SH3L1 5.28/11 931 (5.22/12 643) 2 res. 2–11
Cellular retinoic acid binding protein 2 P29373 RABP2 5.54/12 859 (4.73/27 745) 2 res. 1–10
Rho GDP-dissociation inhibitor 1 P52565 GDIR 5.03/23 907 (5.03/23 207) 3
5. Detoxification and redox proteins
Glutathione S-transferase P P09211 GSTP1 5.56/23 256 (5.44/23 225) 2 res. 1–10
Peroxiredoxin 1 Q06830 PRDX1 6.64/17 189 (8.27/22 110) 3
Superoxide dismutase [Cu-Zn] P00441 SODC 5.74/16 024 (5.70/15 804) 3
Superoxide dismutase [Mn] P04179 SODM 6.89/21 380 (6.89/22 204) 2 res. 25–34
Thioredoxin P10599 THIO 5.07/17 122 (4.82/11 606) 2 res. 1–10
6. Degradation proteins
Cathepsin D P07339 CATD 5.69/30 247 (5.56/26 628) 2 Res. 169–178
Proteasome subunit alpha type 5 P28066 PSA5 4.77/28 148 (4.74/26 411) 2 res. 4–13
Ubiquitin P62988 UBIQ a 5.44/8 260 (6.55/8565) 2 res. 1–10
Ubiquitin P62988 UBIQ b 6.86/8 313 2 res. 1–15
7. Other proteins
Flavin reductase P30043 BLVRB 7.14/19 993 (7.31/21 988) 2 res.1–9
Phosphatidylethanolamine-binding protein P30086 PEBP a 6.82/18 386 (7.43/20 965) 2 res. 1–10
Phosphatidylethanolamine-binding protein P30086 PEBP b 7.15/17 930 2 res. 1–10
U3 small nucleolar RNA-interacting protein 2 O43818 U3IP2 5.90/22 608 (6.74/50 443) 2 res. 15–24
8. Serum proteins
Serum albumin P02768 ALBU multiple forms (5.92/69 367) 3
Serotransferrin P02787 TFRE multiple forms (6.81/77 050) 4
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Table 1. Continued
Protein name AC number Abbreviated
name
Exp. pI/MW
(theoretical)
ID
methodsa)
N-terminal
residues
Ig/gamma-1- chain C region P01857 IGHG1 multiple forms (8.46/36 106) 4
Ig/gamma-1- chain C region P01857 IGHG1 multiple forms (8.46/36 106) 4
Haptoglobin P00738 HPT a 5.74/17 422 (6.13/45 205) 2 res. 19–28
Haptoglobin P00738 HPT b multiple forms (6.13/45 205) 4
Alpha-1-antitrypsin P01009 A1AT multiple forms (5.37/46 736) 4
Hemoglobin alpha subunit P69905 HBA 5.83/12 007 (8.73/15 126) 2 res. 1–7
Hemoglobin alpha subunit P69905 HBA multiple forms (8.73/15 126) 4
Transthyretin P02766 TTHY 5.54/14 022 (5.35/13 761) 2 res. 21–27
Apolipoprotein A-I P02647 APOA1 5.22/24 311 (5.27/28 079) 2 res. 25–32
a) Identification methods: 1, Western blotting; 2, N-terminal sequencing by automated Edman degradation; 3, gel matching with previously
identified protein spots by MALDI-TOF and N-terminal sequencing (see [6]); 4, gel matching with human plasma of SWISS-2D PAGE.
Figure 3. Cytoskeleton and associated proteins. The panel shows differences of spot features between BCT and NAT. Differential expres-
sion of spot density was calculated as Vol%. The differences in expression between breast cancer and normal adjacent tissues were ana-
lyzed by the Student’s t-test: *p,0.05 was considered significant; **p,0.01 highly significant; ***p,0.001 very highly significant. The data
in the graphs are expressed as mean number 6 SD.
Recently, several authors [8] have suggested the existence
of a relationship between actin organization and changes in
actin isoform expression with the ability of cancer cells to
form metastases.
Two other cytoskeletal proteins, TPM4 and TPM2, were
identified in all tumor tissues, while small amounts or even
traces were observed in the non-tumoral counterpart. TPM4
was differentially expressed at a higher significance level,
while the TPM2 intensity level was more variable among
patients. TPM is a major structural protein associated with
the actin microfilaments. Multiple TPM isoforms have been
reported in several cell lines, including breast cancer cells [6],
and some of them have been thought to be associated with
the metastatic potential of several primary tumors [9].
Another interesting protein significantly overexpressed
in the tumor samples is transgelin 2. Recently, the over-
expression of transgelin 2 mRNA was reported in a large
percentage (69%) of hepatocellular carcinomas [10], which
suggests its potential role as a diagnostic marker for cancer
detection.
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Figure 4. Metabolic enzymes. Spot comparison was performed as described in Fig. 3.
Figure 5. Molecular chaperones. Spot comparison was per-
formed as described in Fig. 3.
3.2 Metabolic enzymes (Fig. 4)
In this category of proteins, we identified five enzymes of the
glycolytic pathway: ALDOA, TPIS, G3P2, PGK1, ENOA,
which are collectively overexpressed in the tumor tissue vs.
the non-tumoral counterparts. This observation appears to be
of particular interest when considering the anaerobic shift of
the metabolism of cancer cells, already described in the pio-
neering work of Warburg [11] and presently used for clinical
cancer detection by FDG-PET ((18)F-fluorodeoxyglucose-
Positron Emission Tomography) imaging analyses [12].
Moreover, these data confirm our previous report show-
ing increased levels of glycolytic enzymes in breast cancer
cells vs. non-tumoral mammary-derived cells [4]. It is also
likely that the incremented expression level of some glyco-
lytic enzymes may be related to additional functions per-
formed by the cells. As an example, G3P2, besides its pivotal
role in the glycolytic pathway and energy production, fulfils a
multiplicity of functions such as membrane fusion, micro-
tubule bundling, phosphotransferase activity, and nucleic
acid binding, all aspects deserving attention from the point
of view of transformation [13, 14].
3.3 Molecular chaperones (Fig. 5)
Presently, we have identified only two proteins in this cate-
gory: CRTC and PPIA. Both of them are significantly over-
expressed in the tumor tissue vs. the non-tumoral counter-
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Figure 6. Cell cycle regulation and differentiation. Spot comparison was performed as described in Fig. 3.
Figure 7. Detoxification and redox proteins. Spot comparison was performed as described in Fig. 3.
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Figure 8. Protein degradation. Spot comparison was performed as described in Fig. 3.
Figure 9. Other proteins. Spot compar-
ison was performed as described in
Fig. 3.
part, stressing the hypothesis that they have a function in
cancer. CRTC has been shown to be overexpressed in human
breast by other authors [15], and also in bladder carcinomas
[16]. Recently, it has also been demonstrated that calreticulin
has a role in regulating p53 function by affecting its rate of
degradation and nuclear localization [17]. Likewise, PPIA has
been found to be associated with the growth of colon cancer
cells [18].
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3.4 Proliferation and differentiation regulators (Fig. 6)
We identified four proteins in this category: RABP2, SH3L1,
1433Z and GDIR. RABP2 is a retinoid-binding protein,
thought to regulate the access of retinoic acid to the nuclear
retinoic acid receptors, and therefore to participate in a reg-
ulatory feedback mechanism to control the action of retinoic
acid on cell differentiation. This protein was found among the
most variable within the tumor samples: a result suggesting
that its overexpression, when present, may be used to dis-
criminate among subtypes of ductal infiltrating carcinomas.
The 1433Z family exhibits diverse biological activities, and
may be involved in regulating cell division, differentiation,
survival, apoptosis [19–21] and cancer [22, 23]. It is noteworthy
that one of the two isoelectric forms is significantly over-
expressed in the tumor samples, while the other is more vari-
able. Similarly, the expression level of SH3L1, a gene product
belonging to the SH3BGR (SH3 domain-binding glutamic
acid-rich-like protein) family and structurally related to thio-
redoxin (Trx) super family [24], was found to be rather variable.
Conversely, GDIR (Rho GDP-dissociation inhibitor 1)
was found significantly overexpressed in the tumor samples
vs. the non-tumoral counterparts.
3.5 Detoxification and redox proteins (Fig. 7)
Detoxification and redox proteins are related enzymes per-
forming important roles in cell catabolism and protection
against metabolic stresses. Indeed, experimental evidence
has suggested that oxidative stress mediates various cellular
responses, and that, in turn, the control of reduction/oxida-
tion (redox) is fundamental in maintaining the homeostasis
of the whole organism. The group includes the following
enzymes: SODC, SODM, THIO, PRDX1, GSTP1, which
were collectively overexpressed in all of our cancer-derived
proteomics. Currently, there is much interest in the thior-
edoxin and glutathione systems, due to their major role as
redox systems in animal cells and putative targets for cancer
therapy (see [25] for review). In recent years, the peroxi-
redoxin system has also received much attention for its high
antioxidant efficiency. The mammalian Prdx gene family has
six distinct members located both in the cytoplasm and in
various subcellular locations, including peroxisomes and
mitochondria. Some of the Prdx members also have effects
on cell differentiation and apoptosis and have been found to
be overexpressed in breast cancer [26].
3.6 Protein degradation (Fig. 8)
The protein-degradation machinery plays an important role
in protein homeostasis and cellular health. Within this cate-
gory, we found three enzymes significantly overexpressed in
the cancer tissues, namely, CATD, UBIQ, and PSA5.
Cathepsin D is a lysosomal protease involved in protein
catabolism and is supposed to play important roles in anti-
gen processing, degenerative diseases, and cancer progres-
sion. In breast cancer it has been associated with an
increased risk of relapse and metastasis [27].
Figure 10. Serum proteins. Spot comparison was performed as described in Fig. 3.
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Our present results, showing its consistent over-
expression in the tumor samples vs. the non-tumoral coun-
terparts, add meaning to the recent statement by Rochefort et
al. [27] confirming “the clinical value of cathepsin D as a
prognostic marker in breast cancer, when using well-stan-
dardized assays.”
Similarly, our data confirm UBIQ and PSA5 as reliable
candidate markers for breast carcinomas [28]. Indeed, the
ubiquitin-proteasome pathway system is involved in the
degradation of many key regulatory cellular proteins such as
tumor suppressors and transcriptional regulators, and of
misfolded/denatured proteins, thus regulating different cel-
lular processes including apoptosis, proliferation, differ-
entiation and stress response [29]. Thus, is not surprising
that the pathogenesis of many malignancies and other dis-
orders is correlated, to different extents, with aberrations in
the system.
3.7 Other proteins (Fig. 9)
We have included in this category three proteins with mis-
cellaneous functions, namely, U3IP2, BLVRB, and PEBP.
The protein U3IP2 is a component of a small nucleolar
ribonucleoprotein particle (snoRNPs) thought to participate
in the processing and modification of pre-ribosomal RNA
and to regulate complex-associated protein shuttle between
the nucleus and cytoplasm [30]. The occurrence and over-
expression in cancer tissues renders intriguing its role in
carcinogenesis, but at present more information is needed to
clarify its function.
BLVRB, biliverdin reductase B (flavin reductase-
NADPH), is a member of the insulin receptor substrate
family with serine/threonine/tyrosine kinase activity,
involved in the conversion of biliverdin to bilirubin [31].
Interestingly, BLVRB was also found to translocate to the
nucleus in cells treated with cGMP [32] and to function as
a transcription factor for activator protein 1-regulated
genes and for activation of c-jun and CREB/ATF-2 [33,
34].
Finally, PEBP is a member of the phosphatidylethanol-
amine-binding protein family, also named RKIP (Raf kinase
inhibitor protein). It has been identified in a wide variety of
tissues and is thought to regulate several intracellular sig-
naling pathways, while its deregulation may contribute to
tissue pathology. Among the reported effects, it has been
observed that loss of RKIP expression in prostate cancer cells
confers a metastatic phenotype to them. This effect that may
be reverted by restoring RKIP expression, suggesting a role
of the metastasis suppressor gene for PEBP/RKIP [35].
3.8 Serum proteins (Fig. 10)
The serum proteins are clearly more abundant in the non-
tumoral tissues than in the cancer fragments. This is not
surprising, due to the lower amount of cells and the absence
of neoplastic foci within the host matrix. The majority of
them, i.e., ALBU, A1AT, HPT, IGHG1, HBA, and TFRE,
migrate in the 2-D gels as multiple isoelectric isoforms (see
Table 1). Therefore, adequate evaluation and statistical com-
parison between samples were allowed only for other identi-
fied serum proteins migrating as individual spots (Fig. 10),
one of which, the TTHY, showed a highly significant differ-
ence in expression in normal vs. cancer tissues.
4 Concluding remarks
This study demonstrates quantitative and qualitative differ-
ences in the proteomic profiles between breast cancer tis-
sues, namely, ductal infiltrating carcinomas, and the non-
tumoral adjacent tissues. The work is intended to offer a new
contribution to breast cancer clinical proteomics from a
functional point of view.
Appreciable differences of protein expression were
detected in all the cancer tissues from the following cate-
gories: cytoskeleton and associated proteins, metabolic
enzymes, molecular chaperones, detoxification and degrada-
tion, and cell cycle regulation proteins. Conversely, almost all
serum proteins displayed lower levels in breast cancer tissue
than in normal adjacent tissue.
The functional role of each category has been described
in the result section.
In conclusion, we suggest that the present collection of
differentially expressed proteins, while signifying a novel
contribution to the molecular biology of breast cancer, may
represent promising candidate biomarkers for molecular-
based diagnosis of breast cancer and for pattern discovery.
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Palermo (ex 60%). The authors thank nurse Gilda Barbera’s
valuable support in sample collection and the excellent coopera-
tion of the Breast Unit Staff, directed by Dr. A. Marrazzo, at the
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